Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975-2008

Yiming Chen, Hagop Kantarjian, Haijun Wang, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

BACKGROUND: With the introduction of all-trans retinoic acid and arsenic trioxide, the management of acute promyelocytic leukemia (APL) has changed dramatically. We performed a population-based study of APL in the United States to determine its incidence and relative survival (RS) during a 34-year period. METHODS: We identified 1397 patients diagnosed with APL between 1975 and 2008 in the Surveillance, Epidemiology, and End Results database. Patients were categorized into 4 age groups and 3 calendar periods. As a comparison, we also reviewed the outcome of APL patients treated at our institution during approximately the same time interval. RESULTS: The incidences of APL increased with time period and patient age. Short- and long-term RS improved with each calendar period, with the greatest improvement occurring between 1991 and 1999; 5-year RS rates were 0.18 for patients diagnosed in 1975-1990, 0.52 in 1991-1999, and 0.64 in 2000-2008. Age was an important predictor of survival. For example, the 5-year RS rate in patients diagnosed in 2000-2008 was 0.38 for patients aged ≥60 years and 0.73 and 0.75 for patients aged <20 years and 20-39 years, respectively. Similar treads of improvements in the survival were observed in APL patients treated at our institution. CONCLUSIONS: The incidence of APL has increased, especially in the last decade. Clinical outcome improved remarkably in patients with APL diagnosed from 1991 to 1999, mainly because of the increased use of all-trans retinoic acid.

Original languageEnglish (US)
Pages (from-to)5811-5818
Number of pages8
JournalCancer
Volume118
Issue number23
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Cohort Studies
Survival
Population
Tretinoin
Incidence
Survival Rate
Epidemiology
Age Groups
Databases

Keywords

  • APL
  • ATO
  • ATRA
  • incidence
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Acute promyelocytic leukemia : A population-based study on incidence and survival in the United States, 1975-2008. / Chen, Yiming; Kantarjian, Hagop; Wang, Haijun; Cortes, Jorge; Ravandi, Farhad.

In: Cancer, Vol. 118, No. 23, 01.12.2012, p. 5811-5818.

Research output: Contribution to journalArticle

Chen, Yiming ; Kantarjian, Hagop ; Wang, Haijun ; Cortes, Jorge ; Ravandi, Farhad. / Acute promyelocytic leukemia : A population-based study on incidence and survival in the United States, 1975-2008. In: Cancer. 2012 ; Vol. 118, No. 23. pp. 5811-5818.
@article{0628ab95f62c43a5b549bf7df0412938,
title = "Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975-2008",
abstract = "BACKGROUND: With the introduction of all-trans retinoic acid and arsenic trioxide, the management of acute promyelocytic leukemia (APL) has changed dramatically. We performed a population-based study of APL in the United States to determine its incidence and relative survival (RS) during a 34-year period. METHODS: We identified 1397 patients diagnosed with APL between 1975 and 2008 in the Surveillance, Epidemiology, and End Results database. Patients were categorized into 4 age groups and 3 calendar periods. As a comparison, we also reviewed the outcome of APL patients treated at our institution during approximately the same time interval. RESULTS: The incidences of APL increased with time period and patient age. Short- and long-term RS improved with each calendar period, with the greatest improvement occurring between 1991 and 1999; 5-year RS rates were 0.18 for patients diagnosed in 1975-1990, 0.52 in 1991-1999, and 0.64 in 2000-2008. Age was an important predictor of survival. For example, the 5-year RS rate in patients diagnosed in 2000-2008 was 0.38 for patients aged ≥60 years and 0.73 and 0.75 for patients aged <20 years and 20-39 years, respectively. Similar treads of improvements in the survival were observed in APL patients treated at our institution. CONCLUSIONS: The incidence of APL has increased, especially in the last decade. Clinical outcome improved remarkably in patients with APL diagnosed from 1991 to 1999, mainly because of the increased use of all-trans retinoic acid.",
keywords = "APL, ATO, ATRA, incidence, survival",
author = "Yiming Chen and Hagop Kantarjian and Haijun Wang and Jorge Cortes and Farhad Ravandi",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/cncr.27623",
language = "English (US)",
volume = "118",
pages = "5811--5818",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Acute promyelocytic leukemia

T2 - A population-based study on incidence and survival in the United States, 1975-2008

AU - Chen, Yiming

AU - Kantarjian, Hagop

AU - Wang, Haijun

AU - Cortes, Jorge

AU - Ravandi, Farhad

PY - 2012/12/1

Y1 - 2012/12/1

N2 - BACKGROUND: With the introduction of all-trans retinoic acid and arsenic trioxide, the management of acute promyelocytic leukemia (APL) has changed dramatically. We performed a population-based study of APL in the United States to determine its incidence and relative survival (RS) during a 34-year period. METHODS: We identified 1397 patients diagnosed with APL between 1975 and 2008 in the Surveillance, Epidemiology, and End Results database. Patients were categorized into 4 age groups and 3 calendar periods. As a comparison, we also reviewed the outcome of APL patients treated at our institution during approximately the same time interval. RESULTS: The incidences of APL increased with time period and patient age. Short- and long-term RS improved with each calendar period, with the greatest improvement occurring between 1991 and 1999; 5-year RS rates were 0.18 for patients diagnosed in 1975-1990, 0.52 in 1991-1999, and 0.64 in 2000-2008. Age was an important predictor of survival. For example, the 5-year RS rate in patients diagnosed in 2000-2008 was 0.38 for patients aged ≥60 years and 0.73 and 0.75 for patients aged <20 years and 20-39 years, respectively. Similar treads of improvements in the survival were observed in APL patients treated at our institution. CONCLUSIONS: The incidence of APL has increased, especially in the last decade. Clinical outcome improved remarkably in patients with APL diagnosed from 1991 to 1999, mainly because of the increased use of all-trans retinoic acid.

AB - BACKGROUND: With the introduction of all-trans retinoic acid and arsenic trioxide, the management of acute promyelocytic leukemia (APL) has changed dramatically. We performed a population-based study of APL in the United States to determine its incidence and relative survival (RS) during a 34-year period. METHODS: We identified 1397 patients diagnosed with APL between 1975 and 2008 in the Surveillance, Epidemiology, and End Results database. Patients were categorized into 4 age groups and 3 calendar periods. As a comparison, we also reviewed the outcome of APL patients treated at our institution during approximately the same time interval. RESULTS: The incidences of APL increased with time period and patient age. Short- and long-term RS improved with each calendar period, with the greatest improvement occurring between 1991 and 1999; 5-year RS rates were 0.18 for patients diagnosed in 1975-1990, 0.52 in 1991-1999, and 0.64 in 2000-2008. Age was an important predictor of survival. For example, the 5-year RS rate in patients diagnosed in 2000-2008 was 0.38 for patients aged ≥60 years and 0.73 and 0.75 for patients aged <20 years and 20-39 years, respectively. Similar treads of improvements in the survival were observed in APL patients treated at our institution. CONCLUSIONS: The incidence of APL has increased, especially in the last decade. Clinical outcome improved remarkably in patients with APL diagnosed from 1991 to 1999, mainly because of the increased use of all-trans retinoic acid.

KW - APL

KW - ATO

KW - ATRA

KW - incidence

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84869502214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869502214&partnerID=8YFLogxK

U2 - 10.1002/cncr.27623

DO - 10.1002/cncr.27623

M3 - Article

C2 - 22707337

AN - SCOPUS:84869502214

VL - 118

SP - 5811

EP - 5818

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -